CL2021000191A1 - Inhibidores de inflamasoma nlrp3 - Google Patents

Inhibidores de inflamasoma nlrp3

Info

Publication number
CL2021000191A1
CL2021000191A1 CL2021000191A CL2021000191A CL2021000191A1 CL 2021000191 A1 CL2021000191 A1 CL 2021000191A1 CL 2021000191 A CL2021000191 A CL 2021000191A CL 2021000191 A CL2021000191 A CL 2021000191A CL 2021000191 A1 CL2021000191 A1 CL 2021000191A1
Authority
CL
Chile
Prior art keywords
nlrp3
nlrp3 inflammasome
inflammasome inhibitors
inhibitors
relates
Prior art date
Application number
CL2021000191A
Other languages
English (en)
Inventor
Nikolaus Johannes Stiefl
Christopher Farady
Nina Gommermann
Philipp Janser
Angela Mackay
Henri Mattes
Juraj Velcicky
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2021000191A1 publication Critical patent/CL2021000191A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de tienopirrolotriazinacetamida de la fórmula (I), en donde R1, R2 y R3 se definen en el presente documento, que inhiben la actividad inflamatoria de la proteína 3 receptora de tipo NOD (NLRP3). La invención se refiere, además, a los procesos para su preparación, composiciones farmacéuticas y medicamentos que los contienen, y su uso en el tratamiento de enfermedades y trastornos mediados por NLRP3.
CL2021000191A 2018-07-25 2021-01-22 Inhibidores de inflamasoma nlrp3 CL2021000191A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18185580 2018-07-25
EP19175246 2019-05-17

Publications (1)

Publication Number Publication Date
CL2021000191A1 true CL2021000191A1 (es) 2021-08-20

Family

ID=67989037

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000191A CL2021000191A1 (es) 2018-07-25 2021-01-22 Inhibidores de inflamasoma nlrp3

Country Status (22)

Country Link
US (1) US20210308140A1 (es)
EP (1) EP3827008A1 (es)
JP (1) JP2021532124A (es)
KR (1) KR20210038877A (es)
CN (1) CN112424207B (es)
AU (1) AU2019309727B2 (es)
BR (1) BR112021000964A2 (es)
CA (1) CA3103943A1 (es)
CL (1) CL2021000191A1 (es)
CO (1) CO2021000537A2 (es)
CR (1) CR20210045A (es)
CU (1) CU20210009A7 (es)
DO (1) DOP2021000019A (es)
EC (1) ECSP21004787A (es)
IL (1) IL280336A (es)
JO (1) JOP20210017A1 (es)
MA (1) MA53388A (es)
MX (1) MX2021000925A (es)
PE (1) PE20210406A1 (es)
PH (1) PH12021550166A1 (es)
SG (1) SG11202012321PA (es)
WO (1) WO2020021447A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021202305A1 (en) * 2020-03-31 2021-10-07 Olatec Therapeutics Llc Method for preventing or treating lung infection and lung inflammation
AU2021255895A1 (en) 2020-04-15 2022-12-15 Janssen Pharmaceutica Nv Pyrrolo[1,2-d][1,2,4]triazine-2-yl-acetamides as inhibitors of the nlrp3 inflammasome pathway
MX2022012897A (es) 2020-04-15 2022-11-14 Janssen Pharmaceutica Nv Pirazolo[1,5-d][1,2,4]triazin-5(4h)acetamidas como inhibidores de la ruta del inflamasoma nlrp3.
CA3176029A1 (en) 2020-04-23 2021-10-28 Daniel Oehlrich Tricyclic compounds as inhibitors of nlrp3
CA3176688A1 (en) 2020-04-30 2021-11-04 Daniel Oehlrich New triazinoindole compounds
WO2021239885A1 (en) 2020-05-28 2021-12-02 Janssen Pharmaceutica Nv Compounds
IL299084A (en) 2020-06-19 2023-02-01 Ac Immune Sa History of dihydrooxazole and thiourea or urea modulating the NLRP3 inflammasome pathway
EP3974415A1 (en) 2020-09-24 2022-03-30 Janssen Pharmaceutica NV Nlrp3 modulators
CA3189887A1 (en) 2020-09-24 2022-03-31 Daniel Oehlrich New compounds
CN114478537B (zh) * 2020-11-13 2024-02-02 上海拓界生物医药科技有限公司 环酰胺并环化合物及其医药用途
MX2023010223A (es) 2021-03-04 2023-09-11 Janssen Pharmaceutica Nv Derivados de 4-amino-6-oxo-piridazina que modulan la nlrp3.
CN117083272A (zh) 2021-03-04 2023-11-17 詹森药业有限公司 调节nlrp3的4-烷氧基-6-氧代-哒嗪衍生物
CN113230240B (zh) * 2021-03-22 2022-12-27 广州医科大学 1,3-二苯基丙-2-烯-1-酮衍生物及其应用
KR20230170692A (ko) 2021-04-13 2023-12-19 유니티 바이오테크놀로지, 인크. 망막 혈관병증을 치료하는 방법
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
KR20240005696A (ko) * 2021-04-29 2024-01-12 얀센 파마슈티카 엔브이 Nlrp3 인플라마좀 억제제로서의 프탈라지논 유도체
IL294231A (en) 2021-06-23 2023-01-01 Yoda Pharmaceuticals Inc History of benzimidazole for the treatment and/or prevention of nlrp3-mediated diseases and disorders
EP4363418A1 (en) 2021-07-01 2024-05-08 JANSSEN Pharmaceutica NV 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides
WO2023028536A1 (en) * 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. 1,2,4-triazine derivatives useful as inhibitors of nlrp3
WO2023044043A1 (en) * 2021-09-17 2023-03-23 Denali Therapeutics Inc. Compounds, compositions and methods
KR20230066899A (ko) 2021-11-08 2023-05-16 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
WO2023118521A1 (en) 2021-12-22 2023-06-29 Ac Immune Sa Dihydro-oxazol derivative compounds
WO2023156643A1 (en) * 2022-02-21 2023-08-24 Sanofi Thienopyrrolotriazine compounds, their preparation and their therapeutic use
US20240034735A1 (en) 2022-07-14 2024-02-01 Ac Immune Sa Novel compounds
US20240101563A1 (en) 2022-07-28 2024-03-28 Ac Immune Sa Novel compounds
WO2024033845A1 (en) * 2022-08-10 2024-02-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR20240022938A (ko) 2022-08-12 2024-02-20 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
WO2024064245A1 (en) 2022-09-23 2024-03-28 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009008906A2 (en) * 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
WO2010128152A1 (en) 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
EP2491050A2 (en) 2009-10-20 2012-08-29 Novartis AG Glycoside derivative and uses thereof
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
DK2975042T3 (en) 2010-06-23 2019-01-21 Hanmi Science Co Ltd Novel fused pyrimidine derivatives to inhibit tyrosine kinase activity
BR112013003388A2 (pt) 2010-08-10 2016-07-12 Celgene Avilomics Res Inc sal de besilato de um inibidor de btk
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
CA2833771C (en) 2011-06-10 2021-08-03 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
PT2786996T (pt) 2011-11-29 2016-11-07 Ono Pharmaceutical Co Cloridrato de derivado de purinona
WO2013185082A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Inhibitors of bruton's tyrosine kinase
PT2892900T (pt) 2012-09-10 2017-11-06 Principia Biopharma Inc Compostos de pirazolopirimidina como inibidores de cinase
SG11201503697TA (en) 2012-11-28 2015-06-29 Intercept Pharmaceuticals Inc Treatment of pulmonary disease
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
EP2989106B1 (en) 2013-04-25 2016-12-14 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors
TR201807321T4 (tr) 2013-11-05 2018-06-21 Novartis Ag Farnesoid x reseptörlerinin modüle edilmesi için bileşimler ve yöntemler.
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
AU2014358868A1 (en) 2013-12-05 2016-06-09 Acerta Pharma B.V. Therapeutic combination of a PI3K inhibitor and a BTK inhibitor
US9981926B2 (en) 2013-12-20 2018-05-29 Novartis Ag Heteroaryl butanoic acid derivatives
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
TN2016000441A1 (en) 2014-05-13 2018-04-04 Novartis Ag Compounds and compositions for inducing chondrogenesis.
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
MY188048A (en) 2014-10-24 2021-11-12 Bristol Myers Squibb Co Indole carboxamide compounds useful as kinase inhibitors
CN107427468B (zh) 2014-12-24 2022-02-25 普林斯匹亚生物制药公司 Btk抑制剂的部位特异性给药
CN106459049B (zh) 2015-06-03 2020-11-27 普林斯匹亚生物制药公司 酪氨酸激酶抑制剂
US20180282310A1 (en) 2015-06-10 2018-10-04 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
WO2017059702A1 (en) 2015-10-09 2017-04-13 Acea Biosciences, Inc Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
KR20180073599A (ko) 2015-11-04 2018-07-02 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 암 치료하는 방법
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US10626116B2 (en) 2016-01-05 2020-04-21 Jiangsu Hengrui Medicine Co., Ltd. Crystalline form of BTK kinase inhibitor and preparation method thereof
US10556903B2 (en) * 2016-04-19 2020-02-11 Innate Tumor Immunity, Inc. NLRP3 modulators
KR101865120B1 (ko) 2016-06-29 2018-06-08 숭실대학교 산학협력단 테스트 노드 기반의 무선 측위 방법 및 그 장치
SG11201811255WA (en) 2016-06-29 2019-01-30 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
GB201712282D0 (en) * 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
US11926600B2 (en) * 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors

Also Published As

Publication number Publication date
BR112021000964A2 (pt) 2021-04-20
PH12021550166A1 (en) 2021-09-13
CU20210009A7 (es) 2021-08-06
US20210308140A1 (en) 2021-10-07
CN112424207A (zh) 2021-02-26
MA53388A (fr) 2021-06-02
CR20210045A (es) 2021-06-18
KR20210038877A (ko) 2021-04-08
IL280336A (en) 2021-03-01
MX2021000925A (es) 2021-03-31
CO2021000537A2 (es) 2021-01-29
DOP2021000019A (es) 2021-02-15
ECSP21004787A (es) 2021-03-31
CN112424207B (zh) 2024-03-19
EP3827008A1 (en) 2021-06-02
JOP20210017A1 (ar) 2021-01-21
AU2019309727B2 (en) 2021-12-23
AU2019309727A1 (en) 2021-01-07
PE20210406A1 (es) 2021-03-02
WO2020021447A1 (en) 2020-01-30
CA3103943A1 (en) 2020-01-30
JP2021532124A (ja) 2021-11-25
SG11202012321PA (en) 2021-02-25

Similar Documents

Publication Publication Date Title
CO2021000537A2 (es) Inhibidores de inflamasoma nlrp3
CL2021003012A1 (es) Inhibidores del inflamasoma nlrp3
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
NI202000078A (es) Compuestos heteroaril tetracíclicos
CL2021000907A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020)
DOP2021000183A (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
EA202091512A1 (ru) Производные сульфонилмочевины в качестве модуляторов nlrp3 инфламмасомы
CR20190204A (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer
CO2024001922A2 (es) Inhibidores de nlrp3
CL2022000201A1 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
PE20151501A1 (es) Inhibidores de prmt5 y sus usos
BR112016028642A2 (pt) composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
BR112016028814A2 (pt) ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo?
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
DOP2020000088A (es) Derivados de piridinona y su uso como inhibidores selectivos de alk–2.
UY38550A (es) Compuestos inhibidores de inflamasoma nlrp3, composiciones, combinaciones y métodos relacionados
CO2021001174A2 (es) Inhibidores de ckd8/19
UY38133A (es) Nuevos inhibidores de cdk8/19
CL2020002398A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")